Table 3.
Immunohistochemistry results of endometrial cancer
| Total | With Adenomyosis | Without Adenomyosis | χ2 | P | |
|---|---|---|---|---|---|
| ER | |||||
| Positive | 1174 | 112 (94.87%) | 1062 (90.14%) | ||
| Negative | 123 | 6 (5.13%) | 117 (9.86%) | 2.926 | 0.087 |
| PR | |||||
| Positive | 1111 | 101 (86.32%) | 1010 (85.88%) | ||
| Negative | 182 | 16 (13.67%) | 166 (14.12%) | 0.117 | 0.896 |
| P53 | |||||
| Positive | 807 | 63 (53.39%) | 744 (63.32%) | ||
| Negative | 486 | 55 (46.61%) | 431 (36.68%) | 4.507 | 0.034 |
| Ki-67 | |||||
| Positive | 1230 | 111 (94.87%) | 1119 (96.97%) | ||
| Negative | 41 | 6 (5.13%) | 35 (3.03%) | 1.494 | 0.222 |
| Survivn | |||||
| Positive | 687 | 58 (59.79%) | 629 (62.59%) | ||
| Negative | 415 | 39 (40.21%) | 376 (37.41%) | 0.294 | 0.588 |
| CA125 | |||||
| Positive | 794 | 72 (65.45%) | 722 (66.54%) | ||
| Negative | 401 | 38 (34.55%) | 363 (33.46%) | 0.053 | 0.818 |
ER: Estrogen-receptor; PR: progesterone-receptor.